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Background: Common human diseases are caused by the complex interplay of genetic susceptibility as well as
environmental factors. Due to the environment’s influence on the epigenome, and therefore genome function, as
well as conversely the genome’s facilitative effect on the epigenome, analysis of this level of regulation may
increase our knowledge of disease pathogenesis.
Methods: In order to identify human-specific epigenetic influences, we have performed a novel genome-wide DNA
methylation analysis comparing human, chimpanzee and rhesus macaque.
Results: We have identified that the immunological Leukotriene B4 receptor (LTB4R, BLT1 receptor) is the most
epigenetically divergent human gene in peripheral blood in comparison with other primates. This difference is due
to the co-ordinated active state of human-specific hypomethylation in the promoter and human-specific increased
gene body methylation. This gene is significant in innate immunity and the LTB4/LTB4R pathway is involved in the
pathogenesis of the spectrum of human inflammatory diseases. This finding was confirmed by additional
neutrophil-only DNA methylome and lymphoblastoid H3K4me3 chromatin comparative data. Additionally we
show through functional analysis that this receptor has increased expression and a higher response to the LTB4
ligand in human versus rhesus macaque peripheral blood mononuclear cells. Genome-wide we also find human
species-specific differentially methylated regions (human s-DMRs) are more prevalent in CpG island shores than
within the islands themselves, and within the latter are associated with the CTCF motif.
Conclusions: This result further emphasises the exclusive nature of the human immunological system, its divergent
adaptation even from very closely related primates, and the power of comparative epigenomics to identify and
understand human uniqueness.Background
In the past half century there has been a dramatic in-
crease in chronic inflammatory and metabolic common
human diseases [1,2]. This is too rapid a time frame to
be due to changes in common genetic allele frequency;
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tal effects can influence the genome through the more
malleable epigenome [4,5]. Thus, by studying this level
of regulation, we may identify the genes and pathways
modified by this modern environment that are involved
in the pathogenesis of these diseases.
Over a far longer evolutionary term, the environmental
pressure experienced since the last common primate an-
cestor has been a major driver in the human phenotype
we see today. Comparative genetic analyses of human [6]
with close relatives such as the chimpanzee [7], rhesusLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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these alterations at the sequence level. Accelerated regions
have highlighted potentially modified neurological [13,14]
and anatomic [15] pathways, human-specific duplications
have been implicated in enhanced neuronal migration [16]
and human-specific deletions have identified lost regula-
tory regions [17]. Comparative epigenomics has only re-
cently started to be explored in a number of tissues
[18-22]. This regulatory level has a plausible role as a
rapid adaptive response mechanism to external change. It
is therefore hypothesized to hold insights into recent en-
vironmental effects impacting on genomic activity [23,24].
Furthermore, this regulatory change can occur gradually,
minimizing effects on viability.
To fully understand human susceptibility to disease we
require precise knowledge of what makes us unique. This
will be the result of the integration of genetic and epigen-
etic differences, and their interplay with the environment.
The aim of this study was to find the most substantial hu-
man species-specific DNA methylome variation in periph-
eral blood, a tissue type integral to immune responses, by
triangulation analysis [25] between human, chimpanzee,
and rhesus macaque. The epigenomic mark of DNA
methylation is critical for development and is strongly as-
sociated with gene regulation. This human-specific DNA
methylome variation will be driven by obligatory and fa-
cilitative genetic factors, as well as pure epigenetic effects
[26]. Genetic divergence in orthologous loci will contrib-
ute to methylome variation; by alterations in transcrip-
tion factor binding sites (TFBSs) that act as methylation
determining regions (MDRs) [27]; or associated with CpG
density changes, due to gain or loss of species-specific
CpGs [28], impacting on CpG island (CpGi) strength
[29-31]. The major proportional components of peripheral
blood cells are similar between all three species [32-34];
therefore, methylation differences affecting the major cell
type fractions or multiple subtypes will be detected. Finally
there is the possibility that changes in DNA methylation
may be driven as a response to the different environmen-
tal stimuli encountered by the primates [35].
The observed methylation state may play an active role
in expression, or may passively accumulate due to lack of
transcription factor binding, but in either situation is still
informative of robust variation in effectors and regulation.
Thus, the possible identification of environmentally driven
DNA methylation variation between the species could be
highly informative in terms of the analysis of the patho-
physiology of human disease, particularly if this was able
to quantify modern lifestyle disease risk factors [4,36]. The
various environmental pressures, bottlenecks, and drift
over the separate courses of these species since the last
common ancestor of human and chimpanzee (approxi-
mately 5 to 6 million years ago (MYA)) [37] will have then
left not only a genetic [38] but also an epigenetic human-specific signature. Understanding these modifications will
reveal insights into human-specific physiology and poten-
tially human-specific responses to environmental change
and vulnerabilities to disease [39].
Methods
DNA methylomes
DNA was extracted from peripheral blood of five chim-
panzees (Pan troglodytes; three males, two females) and
five rhesus macaques (Macaca mulatta; three males, two
females). Samples were taken from captive individuals at
Tierpark Nordhorn, Basel Zoo, Leipzig Zoo and at the
German Primate Centre during routine health checks and
not specifically for this study. Microsatellite analysis con-
ducted at the German Primate Centre verified that re-
spective individuals are not related. Sample collection
adhered to the American Society of Primatologists' Princi-
ples for the Ethical Treatment of Non-Human Primates
[40]. Human DNA was derived from 10 anonymous
healthy human subjects (also 60% male).
Analysis was performed in whole peripheral blood in all
primates in order to identify significant outlier changes.
The proportional makeup of cells present in the blood,
which are predominately neutrophils (47 to 67%) and lym-
phocytes (28 to 37%) in human [32], has very similar ra-
tios in chimpanzee (male neutrophils 59%, lymphocytes
28%; female neutrophils 49%, lymphocytes 41% [33]) and
rhesus macaque (neutrophils approximately 67% and lym-
phocytes 26 to 35% [34]). Whilst additional populations of
cells, as well as extra subtypes such as lymphocytes, T cells
(CD4, CD8, and others), B cells, natural killer cells, and
others, will each possess their unique subtle signatures,
this is far below the resolution of this study as only large
significant global changes were examined.
DNA samples were pooled for each species at equal con-
centration for each individual to obtain averaged methy-
lomes and reduce individual genotypic polymorphism
effects. Methylated DNA immunoprecipitation (MeDIP
was then executed according to the Auto-MeDIP-seq
protocol as described in Butcher and Beck [41] and se-
quenced on an Illumina GAIIx. We generated a data set of
over 171 million uniquely mapped fragments (>342 million
mapped paired-end reads). Of these, 40,797,356 were hu-
man, 64,610,346 were chimpanzee and 65,824,761 ma-
caque. This was performed with paired end reads of 36 bp
with average fragment sizes of 197 bp in human, 222 bp in
chimpanzee, and 217 bp in macaque.
MeDIP-seq data were processed using MeDUSA v1.0
(Methylated DNA Utility for Sequence Analysis) [42].
Sequence quality control was performed using FASTQC
[43]. MeDUSA utilized BWA (v0.5.8) [44] for alignment
to reference genomes. Human was aligned to hg19,
chimpanzee to panTro2 and macaque to rheMac2 ob-
tained from University of California Santa Cruz (UCSC).
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lowing alignment a number of filtering steps were per-
formed. Initially SAMtools v0.1.18 [45] was used to
remove reads with low alignment score (q < 10). Only
those forming a correctly aligned pair were kept. A final
filtering step removed potential PCR artifacts by discard-
ing all but one read pair within groups of non-unique
fragments. MeDIP specific quality control was per-
formed using MEDIPS (v1.0) [46]. Bigwig files represent-
ing normalized read depth (reads per million or rpm)
were generated for viewing in the relevant genomes. The
corresponding methylome data were deposited in Gene
Expression Omnibus (GEO) under accession number
GSE48942.
Differential methylation region analysis
Regions enriched for methylated reads were identified
using both MACS v1.4.1 [47] and BayesPeak v1.8 [48].
Both programs were run using the alignment files ob-
tained from their native genome (that is, prior to liftOver).
MACS was run using the parameters -nomodel with
bandwidth set to the alignment calculated fragment length
(human = 197, chimpanzee = 220 and rhesus macaque =
217) and shiftsize to half the fragment length. A P-value
threshold of 1 × 10-3 was used for peak selection. Bayes-
Peak was run with default values in multicore mode.
Having identified the regions enriched for MeDIP-seq sig-
nal, to enable comparative analysis of these peak regions,
the MACS and BayesPeak output for chimpanzee and
rhesus macaque was lifted to human hg19 using liftOver
[49] with minMatch = 0.7. This parameter is appropriate
due the recent shared evolutionary history of these species
[50]. Subsequently, human-specific differentially methyl-
ated regions (s-DMRs) were located through a series
of intersection analyses utilizing the BEDTools [51] com-
mand intersectBed (v2.10) with a minimum overlap
threshold of 1 bp.
Regions hypomethylated in human were defined as re-
gions containing peaks in chimpanzee and rhesus ma-
caque but not in human. Firstly, a single peak set was
defined for both chimpanzee and macaque by excluding
any MACS peaks that failed to intersect with a Bayes-
Peak call. Secondly, shared peaks were identified be-
tween the chimpanzee and macaque peak set prior to
intersecting with both the human MACS and human
BayesPeak set. Hypomethylated s-DMRs were defined by
the presence of a shared chimpanzee/rhesus macaque
peak in the absence of a human peak from either soft-
ware output. The chimpanzee MACS peak location lifted
to human determined the coordinates of the s-DMR. A
similar process was followed to identify hypermethylated
s-DMRs in human. Any regions found in both MACS
and BayesPeak in human, but that did not intersect any
peak in chimpanzee or rhesus macaque, were isolated.Potentially, false positive hypermethylated regions could
be generated, caused by an issue in the conversion from
non-human primate genome to human genome. To re-
move such errors, all potential hypermethylated regions
were lifted back to their non-human primate genome
and then again to human. Only those peaks mapping
back to the original location were maintained as hyper-
methylated s-DMRs for further analysis. We furthermore
excluded all of the declared poor mappability regions as
identified by ENCODE [52].
To benchmark the robustness of our peak calling
method we compared the raw read counts for each spe-
cies within their native genomes within the lifted s-
DMRs coordinates. Normalizing reads between all three
of the species to a human constant ((Reads/Total aligned
individual species reads) × Total human reads), we
showed that there were significant differences in methy-
lation signal prior to liftOver. The comparisons between
human and chimpanzee and human and rhesus macaque
are significantly greater in the hypermethylated s-DMRs
and are significantly less in the hypomethylated s-DMRs,
versus the difference between chimpanzee and rhesus
macaque in these locations (all human differences versus
non-human differences pairwise comparisons; Wilcoxon
tests all P < 2.2 × 10-16; data not shown).s-DMR enrichment analysis
Feature enrichment data were visualized using Epiex-
plorer [53]. Significance was calculated by Genomic
Hyperbrowser [54] via hypothesis overlap testing with
ChromHMM GM12878 (P-values were computed under
the null model defined by the following preservation and
randomization rules: preserve segments (T2), segment
lengths and inter-segment gaps (T1); randomize posi-
tions (T1), Monte Carlo (MC) false discovery rate (FDR)
threshold 0.005). Gene enrichment via GREAT 2.0.2
Region-Based Binomial Analysis was performed with the
default Basal + extension parameters (constitutive 5.0 kb
upstream and 1.0 kb downstream, up to 1000.0 kb
max extension). Curated regulatory domains were
included. For the hypermethylated s-DMR repeat en-
richment, the control set was calculated within Epiex-
plorer [53] by reshuffling the genomic positions while
retaining the overall number of regions and the distri-
bution of region sizes.CpG islands and shores
CpGi annotation was obtained from Ensembl (build 64).
CpGi shores were defined as regions extending 2,000 bp
upstream and downstream of each CpGi. The BEDTools
[51] function intersectBed, using a minimum overlap of
0.5, was used to determine the number of s-DMRs
within each feature.
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FASTA sequence for each of the s-DMRs was obtained
from the reference sequence for human and the ortholo-
gous sequence obtained for chimpanzee and rhesus
macaque via LiftOver [49] with the BEDTools [51] Fas-
taFromBed function. The transcription factor affinity
prediction tool TRAP [55] (multiple sequences) was im-
plemented with the 904 TRANSFAC [56] motifs (trans-
fac_2010.1 vertebrates), background model of human
promoters, and Benjamini-Hochberg multiple test cor-
rection. DMRs greater than 5 kb were excluded from
this analysis. The SP1 motifs investigated included
SP1_01, SP1_Q6, SP1_Q6_01, SP1_Q4_01, SP1_Q2_01
and SP1_02; and the RFX family members included
RFX1_01, RFX1_02, RFX_Q6 and EFC_Q6. The empir-
ical P-value calculation for CTCF was derived by
randomization with R (4 by 1,000×). A set of random
hypomethylated and hypermethylated s-DMRs, from the
total set of shared chimpanzee and rhesus macaque
peaks, and all human peaks, respectively, that overlap
CpGis were selected and TRAP [55] motif prediction
scores were calculated for CTCF_01 and CTCF_02 in
the human as well as orthologous chimpanzee and rhesus
macaque sequences (via LiftOver and FastaFromBed).
Those results that exceeded the observed human CTCF
motif divergence were then calculated.
Exons and gene body methylation
Hypomethylated sDMRs located in CpGis were further fil-
tered to obtain a subset associated with 5′ promoter re-
gions. The exons associated with the selected promoters
were identified and their methylation status was compared
in order to detect inverse changes in gene body methyla-
tion. This was performed by identifying MACS peak re-
gions in the human data within the exons and comparing
the MACS score (the transformed P-value attributed to
the peak) between species. If no peak was found within an
exon for either chimpanzee or rhesus macaque, a score of
0 was given. The resulting regions were ranked according
to differential MACS score.
Statistical analysis
All other statistical analyses were performed in the R en-
vironment [57]. Chi-squared calculations for enrichment
for hypomethylated s-DMRs, were compared with the
combined chimpanzee and rhesus macaque peak set
(94,799 peaks) and those for hypermethylated s-DMRs,
with the total human peak set (133,494). For the genomic
feature intersection calculations, the Bayes Peak con-
firmed MACS peak coordinates were used.
Additional epigenomic datasets
Neutrophil MethylSeq (digestion with HpaII followed
by sequencing) data from Martin et al. [19] for fourhumans and four chimpanzees was accessed from GEO
accession number GSE22376. Results were expressed as
the probability p(U) that the site is unmethylated, and vary
between 0 (methylated site) and 1 (unmethylated site).
The probability of being methylated was then taken as 1 -
p(U), with 0 = unmethylated and 1 = methylated. Values
across the two human CpGis and chimpanzee CpGis were
averaged across the island. Comparative H3K4me3 ChIP-
seq data from Cain et al. [21] were accessed via GEO
(GSE24111). These data were derived from B cells (lym-
phoblastoid cell line) from three humans, three chimpan-
zees and three rhesus macaques.
Functional analysis of Leukotriene B4 Receptor
Materials
LTB4 and LY293111 were purchased from Cayman Chem-
ical (Ann Arbor, MI, USA). Calcium ionophore (A23187)
was purchased from Sigma-Aldrich (Dorset, UK). All
other materials were purchased from Life Technologies
(Carlsbad, CA, USA) unless otherwise stated.
Isolation of peripheral blood mononuclear cells
Isolation of human PBMCs was performed by density
centrifugation using Polymorphprep (Axis-Shield, Oslo,
Norway) according to the manufacturer’s protocol. The
study was approved by the Research Ethics Committee
of Guy’s Hospital REC (no: 09/H804/077) and partici-
pants had provided written consent prior to any proced-
ure. In brief, blood collected over 5.4 mmol/L EDTA
was layered over an equivalent volume of Polymorphprep
and centrifuged (500 g) for 35 minutes at 20°C. PBMCs
collected were resuspended in 1:1 volume of RPMI:H2O to
restore osmolarity. After incubation with RBC lysis buffer
(eBiosciences, San Diego, CA, USA) to eliminate erythro-
cyte contamination, cells were then washed twice in
phosphate-buffered saline and counted using a Nucleo-
Counter (Chemometec, Allerød, Denmark). Isolation of
rhesus macaque PBMCs was performed at the German
Primate Centre by standard protocols for human PBMCs
using Biocoll 1.077 g/ml (Biochrome, Cambridge, UK) with
an extended centrifugation step (45 minutes) for separation
of PBMCs. Separate PMBC aliquots in Trizol and in
medium (HEPES-buffered RPMI + 10% fetal calf serum +
Pen/Strep) were transported.
Real-time PCR
Total RNA was extracted from cells lysed in Trizol (Life
Technologies) using QIAshredder columns and a RNeasy
mini kit (QIAGEN, Venlo, Limburg, Netherlands) with
TURBO DNase (Ambion, Life technologies, Carlsbad,
CA, USA) treatment following the manufacturer’s proto-
col. RNA was quantified using a NanoDrop ND 1000
spectrophotometer (Thermo Scientific, Waltham, MA,
USA) and ND-1000 software version 3.2.0. Reverse
Wilson et al. Genome Medicine 2014, 6:19 Page 5 of 18
http://genomemedicine.com/content/6/3/19transcription of RNA was carried out using RevertAid
M-MuLV reverse transcriptase (Fermentas, Thermo Sci-
entific, Waltham, MA, USA) and primed using random
hexamers according to the manufacturer’s protocol. Rela-
tive mRNA expression levels were measured using Taq-
Man Gene Expression Master Mix (Applied Biosystems,
Life technologies, Carlsbad, CA, USA) and the following
TaqMan probe sets: LTB4R- Hs01938704_s1 and 18s
RNA- 4319413E, matching both human and rhesus ma-
caque sequences. RT-PCR was performed on a ViiA 7
Real-Time PCR system (Applied Biosystems) and analyzed
using ViiA 7 software version 1.0.
Calcium mobilization assay
Calcium mobilization assays were conducted using a
FLIPR calcium 4 assay kit (Molecular Devices, Sunny-
dale, CA, USA) as described previously [58,59]. PBMCs
(2 × 105/well) were plated into poly-D-lysine-coated 96-
well plates in RPMI 1640 supplemented with 10 mmol/L
HEPES. Cells were incubated for 1 hour with FLIPR
loading buffer prior to addition of ligand and fluorescent
intensity was measured at 37°C using a Flexstation 3
(Molecular Devices). Results were analyzed with Soft-
Max Pro Software (Molecular Devices).
Ethics
Chimpanzee and rhesus macaque samples were taken
from captive individuals at Tierpark Nordhorn, Basel
Zoo, Leipzig Zoo and at the German Primate Centre
during routine health checks and not specifically for this
study. Sample collection adhered to the American Soci-
ety of Primatologists' Principles for the Ethical Treat-
ment of Non-Human Primates [40]. For the isolation of
human PBMC samples for functional analysis, the study
was approved by the Research Ethics Committee of
Guy’s Hospital (REC no: 09/H804/077) and participants
had provided written consent prior to any procedure.
Results
Primate DNA methylomes
The DNA methylomes of peripheral blood DNA samples
were generated from pooled individuals in order to
reduce the effects of individual genetic variability. These
were of healthy unrelated primates, comprising 10 humans,
5 chimpanzees and 5 rhesus macaques, all with a 60% male
split. Also, uncultured cells were used to avoid the incorp-
oration of additional stochastic artifacts [60] Automated
MeDIP-seq was performed as previously described [41],
and data were processed using the MeDUSA pipeline [42].
The DNA methylomes are displayable in the individual
genomes, human (GRCh37), chimpanzee (CGCS 2.1/Pan-
Trog2) and rhesus macaque (MGSC Merged 1.0/rheMac2)
in the UCSC genome browser in the context of existing an-
notation and are available at [61]. The chimpanzee andmacaque results can also be viewed on the human se-
quence having been converted using the liftOver utility
[49] to enable an initial comparative view.
Human species-specific differentially methylated regions
To find loci with human s-DMRs we first identified robust
enrichment peaks using the MACS v1.4.1 [47] peak-
calling algorithm, but with the additional conservative re-
quirement that regions must also have an overlap with a
BayesPeak v1.8 [48] algorithm result (see Methods). This
additional step reduced the number of potential peaks by
up to approximately 8%. We then identified all human
peaks where no chimpanzee or rhesus macaque peak was
present in the orthologous location (with either algorithm)
to define hypermethylated human s-DMRs, and hypo-
methylated human s-DMRs where no human peak was
present (again with either algorithm) but where both
chimpanzee and macaque peaks were located in common.
A total of 22,758 hypomethylated and 15,858 hyper-
methylated human s-DMRs were identified. All of these
lie in strongly sequence-similar regions between the three
primate genomes, but are also unique within each primate
genome due to the requirement of these s-DMRs to
be able to pass through consistent reciprocal liftOver
[49] steps across the primate genomes. Therefore, whilst
genetic influence on the methylome is strong and high
sequence similarity exists, particularly between human
and chimpanzee (approximately 98.6% [62]) and primates
overall [63,64], substantial numbers of s-DMRs were
identified. Without the additional out-group of rhesus ma-
caque the calculated human-specific set via only a com-
parison with chimpanzee would be 69.2% larger; thus, its
inclusion increases our power to identify true human-
specific modification. The number of hypomethylated
human s-DMRs is moderately greater compared with
hypermethylated s-DMRs, which is likely due to an
increased loss within the human peak set, as these must
pass through reciprocal liftOver to the two slightly less
well-characterized genome sequences of chimpanzee and
macaque. Consistent with this, peaks from human
chromosome 21 lifted via the higher quality chimpanzee
chromosome 21 [65] retained the highest proportion of
peaks of any chromosome (data not shown). These re-
gions are visible as hypomethylated (yellow) and hyper-
methylated (blue) s-DMRs also via the above UCSC tracks
link and are visualized genome-wide in Figure 1 [66].
Genome feature annotation enrichment
We compared the location of human s-DMRs to genomic
functional annotation, as defined by the ChromHMM seg-
mentation analysis [67], using the HapMap line interro-
gated by Encode (B-lymphocyte GM12878 data). We
calculated significance via Epiexplorer [53] and the Gen-
omic Hyperbrowser [54]. This showed a similar pattern in
Figure 1 Genome-wide view of human s-DMRs. Pooled DNA from uncultured whole blood cell samples including both sexes (all 60% male)
were analyzed for each species. Methylated fragments via MeDIP-seq were aligned to the appropriate species’ genome; then peaks were called
within these, using two peak-calling algorithms (MACS v1.4.1 [47] and BayesPeak v1.8 [48]). Triangulation reciprocal LiftOver [49] comparison then
identified human s-DMRs. Outer ring, human chromosomes; blue ring, hypermethylated human s-DMRs (15,858); yellow ring, hypomethylated
human s-DMRs (22,758); green ring, CNV density; inner ring, gene density.
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cant skew towards weak promoters, gene transcrip-
tional regions, and both strong and weak enhancers, but
depletion within strong promoters (Figure 2A,B). This
is comparable to the finding in tissue and reprogram-
ming s-DMRs, with most DMRs in moderate CpG
dense regions [36]. Increased levels of s-DMRs in these
transcription-associated regions may be indicative of thepotential role methylation variability plays in gene body
methylation [68] and splicing [69,70]. The number of
hypomethylated s-DMRs residing over exons is 3,444 and
over introns is 9,848, and for hypermethylated s-DMRs
these numbers are 1,042 for exons and 6,514 for introns.
The more consistent and stronger results of hypomethy-
lated s-DMRs in enhancer regions is consistent with stud-
ies showing these regions may be protected from DNA
Figure 2 Proportional genomic annotation coverage of s-DMRs compared with HapMap B-lymphocyte EBV GM12878 ChromHMM data
[68]. (A) Hypomethylated s-DMRs; (B) hypermethylated s-DMRs. Various genomic annotations were significantly enriched, as defined by this
segmentation analysis, calculated via the Genomic Hyperbrowser [54] (P-value overlap MC * < 0.05, ** < 0.005).
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thermore s-DMR genomic regions are enriched in com-
parison to the rest of the genome for the dynamic fraction
of the DNA methylome as defined by Ziller et al. [73]
(data not shown, χ2 P < 2.2 × 10-16).
Gene enrichment
Gene enrichment analysis of these s-DMR regions was
performed using the Genomic Regions Enrichment of
Annotations Tool (GREAT) [74]. A large number of sig-
nificant biological, human phenotype and disease-related
enrichments were identified by FDR-corrected region-
based binomial analysis (Additional file 1). A smaller set
of intriguing categories were found to be significant in
both the hypo- and hypermethylated s-DMR enrichment
categories. This included monocyte activation and regu-
lation of prostaglandin-endoperoxide synthase activity
for biological processes; hypotrichosis for human pheno-
type; and diverticulitis for disease ontology, which has
not been observed in non-human primates to date [75].
The evolutionary timescale difference between human
and chimpanzee divergence (5 to 6 MYA) and human
population-based polymorphisms (<1 MYA) is large.
Therefore, many potential genetic disease susceptibilities
will be fixed between the species. Nevertheless genome-
wide association study SNPs [76] are enriched in these
s-DMR regions by approximately 1.40× compared to the
genome average (data not shown; χ2 P = 5.09 × 10-3).
Repetitive elements
The hypermethylated s-DMR set was found to be in-
creased within repetitive elements, specifically the SINE
group (Figure 3; via Epiexplorer [53]). Examination ofthis result showed that these hypermethylated s-DMRs
were disproportionally increased within the second
oldest AluS subcategory (χ2 P < 2.2 × 10-16), which still
possesses mobilization ability [77], whilst being propor-
tionally reduced within both the most ancient AluJ and
youngest AluY categories (Additional file 2). Moreover,
hypomethylated s-DMRs also showed this pattern, with
an increase in AluS (χ2 P < 2.2 × 10-16), but also showed
a slight increase in the youngest and most active AluY
(χ2 P = 1.15 × 10-4). Transposable elements constitute
nearly half of the primate genome and there is increas-
ing evidence for their functional role in influencing
expression and potential modulation in human path-
ology [78]. Primate-specific open chromatin regions
(DNAse I hypersensitivity sites) are enriched for trans-
posable elements (approximately 63%) [79] and methyla-
tion changes in trans-species experiments have also
indicated their regulatory potential [80].
CpG islands
s-DMRs are more prevalent in CpG shores than CpG islands
Previously identified tissue-, cancer- and reprogramming-
specific DMRs [81,82] have all been found to be more
prevalent in moderate CpG dense regions surrounding
CpGis, termed CpGi ‘shores’, than within the island them-
selves. Within the CpGis and CpGi shores, we identified
77 hypo- and 45 hypermethylated human s-DMRs, and
821 hypo- and 431 hypermethylated s-DMRs, respectively
(Additional file 3). After accounting for the almost four-
fold larger genome size taken up by shores (approximately
89.5 Mb) than islands (approximately 23.8 Mb), these
s-DMRs were still more prevalent within shore regions
(Figure 4; Wilcoxon test, both hypo- and hypermethylated,
Figure 3 Subcategorization of repeat element increase in hypermethylated s-DMRs via Epiexplorer in comparison with a reshuffled
control set [53] (medium overlap ≥10%). Increased hyper s-DMRs within the SINE group are identified, which comprises predominately Alus.
LINE, long interspersed nucleotide element; LTR, long terminal repeat; RC, rolling circle; snRNA, short nuclear RNA; srpRNA, signal recognition
particle RNA.
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when comparing island and shore s-DMRs with regard to
all possible locations of hypomethylated s-DMRs (all co-
locating chimpanzee and macaque peaks in these regions;
χ2 P = 4.80 × 10-29) and hypermethylated s-DMRs (from
location of all human peaks in these regions; χ2 P = 2.74 ×
10-8) and for s-DMRs combined (χ2 P = 2.94 × 10-32).
Therefore, the proportion of s-DMRs in CpGi shores is far
higher than in islands (14.0 compared to 5.13 per Mb of
feature sequence). However, other features are even more
concentrated with s-DMRs: exons (23.7/Mb), CTCF sites
(26.8/Mb) and DNAse I hypersensitivity sites (40.3/Mb).
Sequence similarity of s-DMRs in CpG islands
Sequence divergence could be contributing to the s-
DMRs within these CpGis [27]. Therefore, to assess
whether there was greater divergence between species
within s-DMRs, we compared the sequence similarity
between the s-DMRs and the total background set of
peaks that these were identified from. However, no sig-
nificant difference in sequence change between humanFigure 4 Human s-DMRs in CpG islands versus CpG island shores. Num
shore (821 and 431), respectively, is corrected for proportion of genome siz
Directly comparing island and shore s-DMRs with regard to possible locatio
macaque peaks in these regions), χ2 P = 2.90 × 10-29, and hypermethylated
P = 1.93 × 10-8; combined χ2 P = 1.80 × 10-32. Therefore, human-specific pe
CpGi shores.and chimpanzee was seen between hypomethylated s-
DMR peaks and the total combined non-primate peaks,
or hypermethylated s-DMR peaks and the total set of
human peaks within CpGis (Wilcoxon test, both non-
significant, P > 0.05; Figure 5). The observed sequence
divergence for all four subsets is at the expected global
genomic level of approximately 99% sequence identity.
This does not rule out sequence influence within these
s-DMRs, but implies that more severe genetic differ-
ences would not have passed our reciprocal liftOver re-
quirements and within these s-DMR regions sequence
change is not more prevalent than the genome average.
Therefore, only minor levels of base change may be con-
tributing to this methylation variation.
Transcription factor binding site modification
Sequence alteration in certain TFBS motifs within CpGis
have been shown to modify local methylation and
thereby act as MDRs [27]. With the availability of both
human s-DMRs from our dataset and sequence data
from these three species, we were able to interrogateber of hypo- and hypermethylated s-DMRs for island (77 and 45) and
e (genomic space for islands = 23.8 Mb and for shores = 89.5 Mb).
ns of hypomethylated s-DMRs (all co-locating chimpanzee and rhesus
s-DMRs (from all location of human peaks in these regions), χ2
aks are more likely than non-human-specific peaks to reside within
Figure 5 Sequence divergence between human and
chimpanzee within peak regions. There was no significant
difference (Wilcoxon P > 0.05 for both) between s-DMRs in islands
and all chimpanzee and rhesus macaque (C&M) combined peaks or
all human peaks in islands.
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specific genetic changes significantly modifying TFBS
motif strength were looked for. To do this we utilized
the Transcription Factor Affinity Prediction (TRAP) tool
[55] and calculated the binding prediction of 904 TFBSs
(TRANSFAC vertebrate V$motifs [56]) within CpGi-
related s-DMRs in human, as well as the orthologous
chimpanzee and macaque sequences.
We performed a global comparison for the total set of
hypomethylated and hypermethylated CpGi s-DMRs by
calculating a single total binding P-value (Benjamini-
Hochberg corrected) for each motif in each of the three
species. This could be performed in these CpG dense,
predominately hypomethylated and classical promoter
regions as a slight MDR motif sequence variation would
be detectable in these highly similar orthologous se-
quences. We visualized this by plotting in two dimen-
sions the difference in P-values (-log10) between human
and chimpanzee (on the y-axis) and human and ma-
caque (on the x-axis) binding scores to identify consist-
ent human directional change (Figure 6A,B). Both CTCF
motifs (CTCF_01 and CTCF_02) showed consistently in-
creased and decreased motif binding in human hypo-
methylated and hypermethylated s-DMRs, respectively
(blue dots in Figure 6A,B; Additional file 4; empirical
P = 0.046). That is, there was an increase in human
CTCF binding compared to both chimpanzee and ma-
caque within hypomethylated s-DMRs, and inversely a
consistent decrease in CTCF binding in hypermethylateds-DMRs. The CTCF motif has been previously identified
as an MDR [27]. This trans-species effect is consistent
with the disruption of CTCF occupancy being linked to
increased methylation, recently observed across numer-
ous human cell types [83], as well as the different role of
CTCF binding regions within open and closed chroma-
tin [84]. However, other potential MDRs, such as SP1
motifs [85,86] and members of the RFX family, did not
show consistent human directional divergence in this
global analysis. One of the most extreme outliers within
the hypermethylated set was for increased human bind-
ing strength of a MeCP2 (MECP2_02) motif. Due to the
critical role of this gene in development and neural func-
tion [87,88], this may represent motif variation that is
contributing genetically to epigenetic effects across mul-
tiple tissues.
Canonical 5′ promoter s-DMRs
From the total s-DMRs within CpGis, a smaller subset
of 53 hypomethylated and 25 hypermethylated s-DMRs
reside within the canonical 5′ promoter region, and as
such would have a recognized strong potential associ-
ation with the expression of these genes [89].
As highly expressed genes are associated with low
gene promoter methylation and high gene body methyla-
tion [90], we ranked these loci by differential gene body
methylation between human and averaged chimpanzee
and rhesus macaque methylation levels in the consensus
transcripts (CCDC) that arise from these promoters
(Table S4A in Additional file 5). The top hypomethylated
promoter with greatest inverse differential in gene body
methylation was the major isoform of LTB4R (Leukotri-
ene B4 Receptor; Figure 7). This 5′ CpGi in fact also
possesses two hypomethylated s-DMRs, with one also
overlapping the CpGi shore region. This promoter
also overlaps the Leukotriene B4 receptor 2 gene (LTB4R2)
[91] and is a bidirectional promoter for CIDEB transcribed
in the reverse direction. As mentioned, the major iso-
form of LTB4R showed higher exonic methylation than
both chimpanzee and rhesus macaque (MACS -log10
P-value 2943.7, versus 2397.8 and 2180.8) than any of the
other 5′ CpGi hypomethylated genes, with these other co-
locating genes (LTB4R2 and CIDEB) showing the inverse
result (Table 1). We excluded any build inconsistencies
influencing this result by also re-aligning to additional
available primate builds (CSAC 2.1.4/PanTrog4 and BGI
CR_1.0/rheMac3) and these all showed the identical com-
parative methylation difference and peak calls within this
LTB4R locus. The gene body methylation analysis within
the set of hypermethylated promoter s-DMRs revealed the
genes GIT1, ABCG4 and RUSC2 as the highest ranked.
However, in this analysis there was not one strong outlier
identified, as there was for the LTB4R result (Table S4B in
Additional file 5).
Figure 6 Change in transcription factor motif binding prediction within s-DMRs between primates calculated via TRAP [55] with TRANSFAC
motifs [56]. (A,B) Difference in binding prediction (total corrected Benjamini-Hochberg -log10 P-value) between human and chimpanzee (y-axis)
and human and rhesus macaque (x-axis) for each motif within the total set of hypomethylated (A) and hypermethylated (B) CpGi s-DMRs.
Known TFBSs with MDR effects are highlighted in color (SP1 in red, CTCF in blue, RFX motif family in green). Both CTCF motifs show a
consistent increase in the hypomethylated s-DMRs, as well as a consistent decrease in the hypermethylated DMRs, with respect to human.
The MeCP2 motif is identified as a strongly increased outlier in the hypermethylated s-DMRs (orange).
Figure 7 Comparative DNA methylation of LTB4R visualized in the UCSC browser. Human hypomethylated s-DMRs (yellow) are shown
in the promoter CpGi (CpG: 99) of LTB4R (major isoform LTB4R-001 outlined in red). Methylation scale is in reads per millions (RPM) for
each species from MeDIP-seq (human, light blue; chimpanzee, orange; rhesus macaque, olive green). As well as reduced promoter methylation,
larger gene-body methylation, which is related to higher expression [69], was also seen in human compared with the other species over the
sole exon (approximately 1.29-fold stronger peak MAC P-value over gene body CpGi (CpG:76)). In this complex locus the promoter of the major
isoform of LTB4R (highlighted with a red rectangle) also co-locates with the gene body of the low-specificity receptor LTB4R2 and CIDEB. LTB4R
has strong expression in all blood subtypes, particularly the myeloid lineage, including monocytes (Additional file 6).
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1 LTB4R ENST00000345363 CCDS9626 LTB4R-001 2,943.7 2,397.8 2,180.8 546.0 763.0 654.5
63 CIDEB ENST00000258807 CCDS32056 CIDEB-001 47.6 205.6 155.5 -158.0 -107.8 -132.9
64 CIDEB ENST00000541830 CCDS32056 CIDEB-201 47.6 205.6 155.5 -158.0 -107.8 -132.9
71 CIDEB ENST00000336557 CCDS32056 CIDEB-002 83.4 374.1 391.4 -290.8 -308.0 -299.4
73 LTB4R2 ENST00000533293 CCDS9625 LTB4R2-002 0.0 456.6 477.1 -456.6 -477.1 -466.8
74 LTB4R2 ENST00000543919 CCDS9625 LTB4R2-201 0.0 456.6 477.1 -456.6 -477.1 -466.8
Methylation scores from MACS -log10 P-values. LTB4R is the most significant. The other co-locating genes, LTB4R2 and CIDEB, rank at the bottom of this set.
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To investigate the strong comparative methylation differ-
ence we had identified in LTB4R, we examined the avail-
able CpGi-focused methylation-sensitive sequence in
neutrophils from Martin et al. [19] for four human and
four chimpanzees. This replicated these findings within
the promoter and exonic CpGis with average methylation
of 18.4% and 70.3% across the orthologous CpGi promoter
of LTB4R, and 75.9% and 62.0% for the exonic CpGi in
human and chimpanzee, respectively (Figure 8; Wilcoxon
P <0.05 for both). This >50% difference in promoter
methylation is a level of change only seen within humansFigure 8 Results of HpaII digestion of LTB4R followed by
sequencing for promoter and gene body CpGs in human (Hs)
and chimpanzee (Pt) (Martin et al. [19] via GEO). Methylation
within the (A) promoter (Prom = CpG:99 in Figure 7) and (B) gene
body (Body = CpG:76 in Figure 7) CpG islands of LTB4R from reverse
scores (1 - p(U)) of all included HpaII MethylSeq sites analyzed by Met-
Map6 in purified neutrophils. These data replicate the significant differ-
ence identified in MeDIP peripheral blood. Four human and four
chimpanzee samples had average methylation of 18.4% and 70.3% in
the promoter (Prom), and 75.9% and 62.0% in the exonic gene body
(Body) orthologous CpGis (Wilcoxon P < 0.05 for both).in cancer tissue studies, as opposed to the very small varia-
tions identified to date in common non-malignant diseases.
We also investigated the available human peripheral blood
bisulfite-seq DNA methylome from Li et al. [92], which
also supports the findings in human with a methylation
level of 3.43% within the promoter CpGi and 82.22% in the
gene-body exonic CpGi.
Primate comparative chromatin data were available
from B-cell lymphoblastoid cell lines [21]. This identified
a significant activating H3K4me3 peak in the LTB4R
promoter of three human samples, but no declared peak
in three chimpanzees or three rhesus macaque samples
(Figure 9). Thus, although the initial findings were iden-
tified in mixed peripheral blood, the strong effect is cor-
roborated in two major blood components; neutrophils
and B lymphocyte-derived.Figure 9 Human-specific H3K4me3 enrichment in the LTB4R
promoter from ChIP-seq data derived from B cells (lymphoblastoid
cell line; data from Cain et al. [21] via GEO). These data identified
significant activating peaks in all three human samples, but the
signal was not strong enough for any peaks to be called in all three
chimpanzee and all three rhesus macaque samples analyzed.
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that variation in cell type composition is not a potential
confounding factor in this DNA methylome analysis
from whole blood-derived DNA. However, we further
excluded this by examining the 500 leukocyte subtype-
related differentially methylated CpG positions (L-
DMPs) identified by Houseman et al. [93]. We find that
none of these CpGs overlap with the entire LTB4R locus.
Furthermore, just 5 of our 15,858 hypermethylated
DMRs (0.032%) and 6 of our 22,758 hypomethylated
DMRs (0.026%) show overlap with these L-DMPs, re-
spectively. Therefore, only 11 or approximately 2.2% of
these 500 L-DMPs co-localize with any of the s-DMRs
identified, indicating that our results are not significantly
enriched for cell type-associated methylation changes.
Furthermore, we examined intra-human variability, via
the MARMAL-AID repository [94] of all performed 450k
DNA methylation array experiments, which includes 1,665
whole blood samples from healthy and non-cancer disease
subjects. These data, even derived from multiple studies
with significant experimental/batch variation, also confirm
consistently low human LTB4R promoter methylation
(mean 29.4%, standard deviation 7.4% and high LTB4R
gene body methylation (mean 87.9%, standard deviation
2.3%) (Figure 10).
Methylation of this LTB4R promoter has previously
been established by Kato et al. [95] to reduce this gene's
expression. LTB4R (aka BLT1 receptor) is a high affinityFigure 10 Data from the MARMAL-AID Human 450k Methylation
array repository [94] for the LTB4R promoter and gene body
CpG islands. These data are derived from 1,665 whole blood samples
from healthy and non-cancer disease subjects from multiple experiments.
This also showed a consistent low average level of human LTB4R
promoter methylation (mean 29.4%, standard deviation 7.4%) and
high average LTB4R gene body methylation (mean 87.9%, standard
deviation 2.3%). Human LTB4R methylation whole blood 1,665
samples.G-protein-coupled receptor for LTB4, a potent chemo-
attractant involved in inflammation and immune response
in the eicosanoid signaling (leukotriene and prostaglandin)
pathway. It has been implicated in the whole spectrum of
inflammatory diseases [96], including asthma [97], inflam-
matory arthritis [98], atherosclerosis [99,100], inflamma-
tory bowel disease [101], and psoriasis [102]. It has also
previously been postulated to play a role in HIV infection
[103]. LTB4R is highly expressed across all blood cell
types, particularly in myeloid cells such as neutrophils
and monocytes (Additional file 6). The LTB4-LTB4R axis
is involved in linking early immune system activation,
neutrophil auto-signaling and swarming [104], and early
effector T-cell recruitment [105], acting as a potent non-
chemokine pathway for cytotoxic effector cell traffic [106].
Interestingly, the Gene Ontology category for the ligand
of this receptor, ‘Leukotriene Production involved in
Inflammatory Response’ (GO:0002540), was significantly
enriched in the GREAT analysis for hypomethylated
s-DMRs (P = 2.76 × 10-5, FDR q = 2.77 × 10-4). This is due
to s-DMRs associated with genes such as ALOX5 (5-LO)
and ALOX5AP (FLAP) within this pathway. Furthermore,
the gene encoding LTA4 hydrolase (LTA4H), which cata-
lyzes the conversion of LTA4 to LTB4, also contains two
intragenic s-DMRs.
Whilst CpG density is inversely associated with CpGi
methylation state [28,29], the human LTB4R promoter is-
land is slightly less CpG dense than the other primates
(18.7% in human, 19.1% in chimpanzee and 19.3% in rhe-
sus macaque), so from this could be expected to be more,
not less, methylated. The total sequence similarity is 98.3%
between human and chimpanzee and 96.3% between
human and rhesus macaque. We examined the compara-
tive TRANSFAC TFBS motif analysis via TRAP for the
LTB4R-associated s-DMRs. This revealed no significant
difference in known MDR’s CTCF or SP1 motifs in this re-
gion. The only highly significant human-specific gain of
binding affinity within this island was for Rfx1 (Regulatory
factor X1, aka Enhancer factor C, V$ECF_Q6), with a sig-
nificant human motif binding P-value of 0.042, and non-
significant chimpanzee (P = 0.635) and rhesus macaque
(P = 0.491) prediction (Additional file 7). As previously
stated, Rfx2, another member of the RFX winged-helix
transcription factor motifs, has been found to contribute
to methylation variation in MDRs [27], although whether
one motif would be expected to lead to such a consider-
able difference in methylation is not certain. Lienert et al.
[27] identified an incremental additive effect of multiple
MDR motifs required to modify methylation to this level,
thus possibly implicating additional non-genetic or envir-
onmental factors in this locus. The RFX1 motif shows
human-specific binding due to a central T present at
chr14:24779978, which is the C of a CpG in all other pri-
mates. There is also no human common polymorphism at
Figure 11 Expression and signaling of LTB4R (BLT1) in PBMCs
isolated from human and rhesus macaque peripheral blood.
(A) Real-time RT-PCR analysis of LTB4R mRNA in isolated human and
rhesus macaque PBMCs normalized to the reference gene (18s);
results from seven different human donors and from pooled rhesus
macaque PBMCs run as four separate experiments; mean ± standard
error of the mean. (B) Human and rhesus macaque PBMCs were
stimulated with indicated concentrations of LTB4 and intracellular
calcium mobilizations were recorded. Results are expressed as the
ratio of stimulated over basal (S/B) peak calcium fluxes obtained
from three different human donors and pooled rhesus macaque
PBMCs run as four experiments analyzed simultaneously, mean ±
standard error of the mean. (C) Human PBMCs were pre-incubated
for 10 minutes with different concentrations of BLT1 inhibitor
LY22398 and calcium mobilization was analyzed in response to LTB4
(300 nmol/L). Data are presented as mean ± standard error of the
mean percentages of maximum response to LTB4 (N = 3).
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that the modern human motif sequence is identical in
both the archaic Denisovan hominin and the recent high
coverage Altai Neanderthal sequences, thus dating this
particular genetic change to at least prior to approximately
600,000 years ago [107,108].
Different LTB4R (BLT1) mRNA expression and signaling in
human and rhesus macaque cells
To investigate the potential effects of the different epigen-
etic states of the LTB4R (BLT1) promoter, we performed
comparative functional analysis between human and rhe-
sus macaque PBMCs for differential mRNA expression
and signaling. We evaluated the mRNA expression of
LTB4R and the 18s gene as control using TaqMan primers
and probes that are complementary to the gene sequence
in both species. Similar levels of internal control 18s
mRNA were observed in human and rhesus macaque
PBMCs, while 40-fold higher levels of LTB4R mRNA were
identified in human cells (Figure 11A).
LTB4 signaling through the LTB4R/BLT1 receptor in-
duces calcium mobilization in cells known to express
the receptor [58]. To determine whether the increased
expression of LTB4R mRNA in human PBMCs resulted
in functional expression of LTB4R/BLT1, human and
rhesus macaque PBMCs were stimulated with different
concentrations of LTB4 and intracellular calcium flux
was measured (as described in Methods). Human and
rhesus macaque PBMCs responded similarly to a non-
specific calcium activator, the calcium ionophore A23187
(1 μmol/L). However, concentration-dependent responses
to LTB4 were observed in human cells in contrast to rhesus
macaque cells where no specific calcium mobilization was
identified (Figure 11B).
The LTB4R/BLT1 selective antagonist LY223982 was
used to confirm specificity of calcium responses and full
inhibition of calcium mobilization in response to LTB4
was observed in human PBMCs (Figure 11C). These data
support that the identified human-specific differential
methylation pattern within the LTB4R locus may affect
mRNA expression, signaling and function of the LTB4R/
BLT1 receptor.
Discussion
Human uniqueness has arisen due to the accumulation of
genetic, environmental, behavioral and cultural changes
[39,109]. Subtle variation within all these factors, separ-
ately and in complex combinations, also contributes to
disease susceptibility. Additionally, the more extreme dif-
ferences between species contribute to species-specific
disease variation [110]. Higher prevalence of some com-
mon human diseases has been postulated, even whilst
taking environmental differences into consideration, in-
cluding Alzheimer’s disease, coronary artery disease and
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comparatively, to have an excessively heightened inflam-
matory response, with genetic contributions identified, in-
cluding SIGLEC genes [112,113].
By comparative tri-primate peripheral blood DNA
methylation analysis we have identified strong DNA
methylation variation between three primate species, hu-
man, chimpanzee and macaque, and located human-
specific DMRs with potential regulatory consequences.
Many regulatory loci are not constrained across mam-
malian evolution [52] and genetic loss of human-specific
regulatory DNA has previously highlighted regulation
change as a human evolutionary mechanism [17].
Both the hypomethylated and hypermethylated s-DMRs
identified were skewed towards weak promoters, enhancers
and transcribed regions. We also identified these DMRs to
be more prevalent within moderately CpG dense CpGi
shores than the islands themselves, consistent with tissue-,
cancer- and reprogramming-specific changes [82,83]. Pro-
moter hypomethylated regions that are common across
diverse cell types are often found to possess a central region
that remains unmethylated with an outer tidal region that
shifts in a lineage-specific manner modulating associated
gene expression [114]. DNA binding proteins localizing
within these boundary regions, or shores, may help define
these methylation states [18]. Thus, these species-specific
modifications may be acting in similar fashion.
Pathogens have imposed a strong selective influence
on the human genome [115]. Therefore, the unique evo-
lutionary histories of these primates post-speciation
would be expected to lead to unique immune systems.
These strongly divergent differences have been recently
exposed to be extreme within mammals, whereby the
mouse was shown not to reproduce any of the patterns
of gene expression induced by human inflammatory dis-
ease [116,117]. This poor model of human inflammation
was found to perform no better than random. Human
immunological variation is of particular interest due to
the extreme rise of inflammatory diseases within the past
few generations [118]. Combined genetic and new envir-
onmental factors may be driving this increase, with ef-
fects on immune development proposed, and epigenetic
alterations are being explored to explain these immune
system-related diseases [119].
We identified strong human-specific variation in LTB4R,
important in the innate immune leukotriene and prosta-
glandin signaling pathway. Hypomethylated s-DMRs were
identified covering both the promoter CpG island and
shore region of this gene. In addition, inverse species-
specific methylation was identified in the gene body of
LTB4R. These significant DNA methylation differences
identified in peripheral whole blood were replicated in
neutrophil-only data, within both the promoter and the
gene-body region. These data were also consistent with aH3K4me3 ChIP-seq study from primate lymphocyte cell-
lines, with a strong active promoter signature present only
in human. Comparative functional analysis also supported
these large differences found across major blood cell types
by showing human-specific increased expression and lig-
and response in peripheral blood mononuclear cells.
These results are therefore consistent with the epigenetic
‘dimmer switch’ being dialed up in this human locus, in
contrast to on/off human-specific regulatory deletions
[17]. Furthermore, a recently published comparative array
analysis in peripheral blood from Hernando-Herraez et al.
[119], including further primate species (bonobo chim-
panzee, gorilla and orangutan), supports the human-
specific epigenetic state of the LTB4R locus. In this study
three available complementary CpG dinucleotide positions
located within the LTB4R promoter possessed human-
specific hypomethylation.
The LTB4-LTB4R (BLT1) pathway, because of its sig-
nificant immunological role, has been implicated in the
pathophysiology of a number of diseases, including
asthma (including airway hyper-responsiveness, severe
attacks and asthma exacerbations) [97], atherosclerosis,
Alzheimer’s disease [120], obesity-related inflammation
[121], and inflammatory bowel disease [101]. LTB4R is
involved in amplifying T-cell recruitment [122] and a
heightened T-cell response in human compared with
chimpanzee has previously been identified [123]. It is
also of interest to note that up-regulation of LTB4R ex-
pression has been identified in seven out of nine experi-
ments in human via the Expression Atlas [124] and
furthermore that LTB4R expression on T cells is regu-
lated by inflammation and may link innate and adaptive
immune responses [122]. A number of further promoter
associated s-DMRs would also be of interest for further
follow-up, including MAPK15 (mitogen-activated pro-
tein kinase 15), involved in autophagy [125], and the
MECP2 gene, which is mutated in Rett syndrome [126].
The effect of genetic mutation in particular TFBSs on
the methylation state of CpGis has recently been refined
by Lienert et al. [27]. Our identification of human diver-
gent CTCF and RFX1 motif changes are consistent with
these MDR data. These thus shift the genetic set point
of methylation, within these promoters, between these
primates. Additional environmental factors may then
lead to further subtle variation.
Furthermore, from this comparative epigenomic work
we propose the ‘s-DMR hypothesis’ whereby regions of
significant epigenetic difference between humans and
other primates that are highly conserved at the sequence
level may include loci subject to, or indicative of, human-
specific environmental influence, potentially in association
with pathogenic conditions. Thus, focusing on these re-
gions may enable the identification of endemic human en-
vironmental imprints on the epigenome.
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Comparison with our most closely related primate rela-
tives enables insights into human-unique physiology. It is
vital to identify and explain these differences, particularly
as we readily extrapolate disease pathology from models
in other species. Comparative epigenomics enables robust
regulatory modifications to be pinpointed, and by integra-
tion with genetic data, a more complete functional picture
can be elucidated. We have shown within blood tissue that
the DNA methylome is not identically conserved between
these primate species. These variations may be strongly
driven by facilitative genetic means, but also potentially
additional environmental factors. We have identified that
the LTB4R gene is a significant human-specific epige-
nomic outlier, whilst containing minimal genetic differ-
ences. Thus, this finding reveals human-specific change in
the innate immune system that may be a human-specific
susceptibility factor, an inbuilt resultant common primate
response to modern human conditions, or a combination
of both, possibly contributing to the high level of these
common diseases in the current environment.
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youngest AluY categories, but were enriched within the second oldest
AluS set (χ2 P < 2.2 × 10-16), which still possesses mobilization ability [77].
Hypomethylated s-DMRs also show this pattern, with an increase in AluS
(χ2 P < 2.2 × 10-16), but also an increase in the youngest and most active
AluY (χ2 P = 1.15 × 10-4).
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